Tag Archives: revises

FDA revises labeling of Biogen Alzheimer’s drug to emphasize early treatment

The Food and Drug Administration, under heavy criticism over its decision last month to approve Biogen’s Alzheimer’s drug Aduhelm, has revised the medicine’s prescribing information in an effort to focus treatment on the type of patients included in clinical testing. The FDA’s June 7 approval of Aduhelm was made more controversial by the agency’s decision… Read More »